Investor Sentiment (Inverted) -- 4/10
This dimension is inverted -- high bullish sentiment is a negative signal
(crowded trade), while bearish/skeptical sentiment is positive (contrarian opportunity).
DGX scores a 4, reflecting moderately favorable sentiment that limits contrarian upside.
The Street consensus skews toward "Hold/Moderate Buy" with roughly 35% Buy, 56% Hold,
and 9% Sell ratings. Average price targets of $200-$210 bracket the current price of ~$198,
implying only 1-6% upside -- the market believes DGX is roughly fairly valued. Recent target
raises post-Q4 (Mizuho to $235, Barclays to $225, Jefferies to $220) signal growing confidence,
but many come with Hold ratings -- analysts like the story but are not pounding the table.
CEO Jim Davis sold shares in both March 2026 and November 2025, and multiple SVPs sold in
early 2026, with no insider buying observed. The stock is well-liked but not universally loved,
leaving some room for positive surprise but limiting the contrarian opportunity.
Weight: 15%
Analyst Consensus
35% Buy / 56% Hold / 9% Sell
Moderate Buy / Hold split -- not a crowded long, but not bearish either
Avg Price Target
~$200-$210 (+1-6%)
Range $166-$235 | Street believes stock is roughly fairly valued at current levels
Forward P/E
18.6x (fair, not cheap)
Trailing 22.6x compressing to 18.6x on $10.50-$10.70 guided EPS | 73rd pctile of 52-wk range
Insider Activity
CEO + SVPs selling
Davis sold 10K shares (Mar 2026) + 55K shares (Nov 2025) | No insider buying observed
Analyst ratings and recent target revisions
| Firm | Rating | Target | Signal |
|---|---|---|---|
| Mizuho | Outperform | Raised to $235 | Most bullish on the Street -- sees upside from advanced diagnostics growth |
| Barclays | Overweight | Raised to $225 | Constructive on consumer health channel and Corewell CoLab scaling |
| Jefferies | Buy | Raised to $220 | Positive on AD-Detect volumes doubling and Haystack MRD traction |
| UBS | Neutral | Raised to $210 | Acknowledges execution but sees limited upside at current valuation |
| Truist | Hold | Raised to $220 | Raised target but maintained Hold -- likes the story, not pounding the table |
| Bear Case | Sell / Underweight | $166-$170 | PAMA risk, margin dilution from Corewell/Nova, ACA headwinds |
Management vs. Street: management more bullish than consensus
| Topic | Management View | Street View | Assessment |
|---|---|---|---|
| Consumer Health Channel | Growing 30-40% via questhealth.com, approaching $250M in total consumer revenues. New partnerships with WHOOP, Oura, Function Health creating a wellness testing flywheel | Acknowledges growth but questions sustainability in a macro downturn. Consumer wellness spending seen as discretionary and vulnerable | MODERATE GAP -- management has execution track record but macro sensitivity is real |
| Advanced Diagnostics | AD-Detect volumes more than doubling. Haystack MRD gaining traction with breakthrough device designation. Double-digit growth across multiple verticals | Positive on trajectory but pricing in execution risk. Haystack MRD seen as dilutive near-term ($0.25 EPS hit in 2026 from Project Nova) | MODERATE GAP -- Street respects the pipeline but discounts near-term investment drag |
| PAMA Risk | Delayed again to 2027 via PAMA RESULTS Act advocacy. Management actively lobbying for structural reform and framing it as manageable | Not structurally resolved -- potential $100M+ pricing hit if reform fails. Key overhang on valuation | NARROW GAP -- both sides acknowledge the risk; Street gives less credit for legislative outcome |
| Margin Trajectory | Met or raised guidance every quarter in 2025. Test-per-req improvement driving operating leverage. Corewell CoLab scaling to ~$1B revenue | Corewell ramp at low single-digit margins diluting near-term expansion. CFO acknowledged test-per-req pace will slow. Project Nova adds $250-310M cost over 5-7 years | MODERATE GAP -- execution has been strong but near-term dilution headwinds are real |
Institutional positioning and insider activity
| Actor | Action | Signal |
|---|---|---|
| CEO Jim Davis | Sold 10K shares (Mar 2026, ~$206) + 55K shares (Nov 2025, ~$192) | Appears to be 10b5-1 plan sales, but cumulative volume is meaningful. No offsetting insider purchases observed |
| Multiple SVPs | Sold ~$3M+ combined (Feb-Mar 2026) | Broad-based insider selling across senior leadership. All appear programmatic but the pattern is notable |
| Vanguard / BlackRock | ~90% institutional ownership | Dominated by passive/index holders. Core defensive healthcare holding -- not a high-conviction active bet for most |
| Short Interest | Modest (not a battleground) | Hold-heavy consensus and lack of catalyst urgency suggest limited short activity -- no squeeze setup |
Valuation sentiment
| Metric | Value | Interpretation |
|---|---|---|
| Forward P/E | 18.6x | Reasonable but not cheap for a mid-single-digit organic grower with ~10% total revenue growth |
| Trailing P/E | 22.6x | Compression to 18.6x reflects strong expected EPS growth ($10.50-$10.70 guided for 2026 vs. $8.75 TTM) |
| 52-Week Position | 73rd percentile ($157-$214 range) | Not extended but not cheap -- trading in the upper half of its range |
| Dividend Yield | 1.74% | Provides a modest floor but not a yield magnet -- does not drive positioning |
| Upside to Consensus PT | 1-6% | Minimal -- Street believes stock is roughly fairly valued. Limited room for re-rating without positive surprise |
Catalysts and sentiment drivers ahead
Potential Positive Surprises (Would Push Score Lower)
Consumer health channel accelerating beyond 20% CAGR:
Already approaching $250M with WHOOP, Oura, and Function Health partnerships
creating a flywheel. Sustained 30-40% growth would force Street re-rating.
PAMA RESULTS Act passage:
Would remove the single largest structural overhang on the stock. Eliminates
the $100M+ pricing cut risk and could trigger significant multiple expansion.
Haystack MRD commercial inflection:
Less dilutive in 2026, potential revenue tailwind in 2027+. Breakthrough device
designation suggests regulatory pathway is clearing.
AD-Detect volume doubling again:
Anti-amyloid drug expansion (Lecanemab, Donanemab) drives demand for companion
diagnostics. DGX is the scale leader in Alzheimer blood testing.
Corewell margin ramp faster than guided:
Moving from low single-digit to low-teens margins faster than expected would
alleviate the key margin dilution concern.
Potential Negative Surprises (Would Push Score Higher)
PAMA reform failure leading to $100M+ cut in 2027:
If legislative reform stalls, the delayed pricing reset would hit revenues
materially. This is the single largest binary risk to the DGX thesis.
ACA subsidy expiration driving volume loss:
Worse-than-30bps volume impact from Medicaid headwinds would pressure the
base business and undermine the organic growth narrative.
Consumer wellness spending softness:
In a macro downturn, discretionary health testing through questhealth.com
and wellness partnerships could slow materially.
Project Nova cost overruns:
$250-310M total investment over 5-7 years with $0.25 EPS dilution in 2026.
Execution missteps could extend the drag beyond current guidance.
Test-per-req growth plateau:
CFO Sam Samad acknowledged the pace will slow. If the improvement stalls
sooner than expected, operating leverage diminishes.
Score rationale
4/10 (Inverted) -- Limited contrarian opportunity.
Moderately favorable sentiment limits the upside from a contrarian perspective.
Why not lower (2-3): Sentiment is not euphoric or crowded. The 56% Hold rating
and 9% Sell rating show the Street is not unanimously bullish. Meaningful debate exists around
PAMA risk, Corewell margin dilution, and Project Nova investment drag. The spread between bullish
targets ($225-$235) and bearish targets ($166-$170) reflects genuine disagreement, not complacency.
Several catalysts -- PAMA reform, Haystack MRD, consumer health acceleration -- could genuinely
surprise to the upside. The stock is not priced for perfection at 18.6x forward earnings.
Why not higher (5-6): The stock is well-liked across the analyst community. Multiple firms raised targets post-Q4, and the direction of revisions is uniformly positive. Management has met or raised guidance every quarter in 2025, building credibility that the Street increasingly respects. At 35% Buy ratings and rising, the consensus is moving toward bullish, not away from it. The 73rd percentile position in the 52-week range shows the stock is not beaten down. Only 1-6% upside to consensus targets means the market is not ignoring DGX -- it is pricing it roughly correctly. CEO and SVP selling with no insider buying adds a mildly negative signal that offsets some of the positive momentum.
Bottom line: DGX is in a "well-respected compounder, fairly valued" position -- the opposite of a contrarian setup. The Street acknowledges the quality of execution (met or raised guidance every quarter, consumer health growing 30-40%, AD-Detect volumes doubling) but is pricing it at ~18.6x forward P/E, which is reasonable for a mid-single-digit organic grower. The moderate Buy/Hold consensus, minimal upside to targets, insider selling, and 73rd percentile 52-week positioning all signal that sentiment is constructive but not extreme in either direction. A score of 4 reflects a stock where the lack of bearish sentiment limits contrarian opportunity, but the absence of euphoria prevents a lower score. The key variable is PAMA -- legislative reform would be a genuine positive surprise that sentiment has not fully priced in, while reform failure would validate the most bearish cases and could push sentiment more negative (and the inverted score higher).
Why not higher (5-6): The stock is well-liked across the analyst community. Multiple firms raised targets post-Q4, and the direction of revisions is uniformly positive. Management has met or raised guidance every quarter in 2025, building credibility that the Street increasingly respects. At 35% Buy ratings and rising, the consensus is moving toward bullish, not away from it. The 73rd percentile position in the 52-week range shows the stock is not beaten down. Only 1-6% upside to consensus targets means the market is not ignoring DGX -- it is pricing it roughly correctly. CEO and SVP selling with no insider buying adds a mildly negative signal that offsets some of the positive momentum.
Bottom line: DGX is in a "well-respected compounder, fairly valued" position -- the opposite of a contrarian setup. The Street acknowledges the quality of execution (met or raised guidance every quarter, consumer health growing 30-40%, AD-Detect volumes doubling) but is pricing it at ~18.6x forward P/E, which is reasonable for a mid-single-digit organic grower. The moderate Buy/Hold consensus, minimal upside to targets, insider selling, and 73rd percentile 52-week positioning all signal that sentiment is constructive but not extreme in either direction. A score of 4 reflects a stock where the lack of bearish sentiment limits contrarian opportunity, but the absence of euphoria prevents a lower score. The key variable is PAMA -- legislative reform would be a genuine positive surprise that sentiment has not fully priced in, while reform failure would validate the most bearish cases and could push sentiment more negative (and the inverted score higher).
Data sourced from Stock Analysis, MarketBeat, TipRanks, and Seeking Alpha. Q2-Q4 2025 earnings transcripts. Institutional holdings data from SEC 13F filings.